RecruitingNot ApplicableNCT04421846

Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis

COLETTE : Study of the Pathophysiology of Status Epilepticus and Dysimmune Encephalitis and Identification of Valuable Biomarkers

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

400 participants

Start Date

Nov 25, 2020

Study Type

INTERVENTIONAL

Conditions

Status Epilepticus Dysimmune Encephalopathy

Summary

COLETTE is an interventional study for which blood, cerebrospinal fluid and post-mortem tissues are collected in patients with status epilepticus or epilepsy associated to dysimmune encephalitis as well as in control patients, to better understand the pathophysiology of these severe epileptic disorders.

Eligibility

Min Age: 2 Years

Inclusion Criteria15

Group 1:
Patients aged 2 years or above, with status epilepticus.
Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
Patients or relatives have been informed and given free informed and written consent to participate
Patients under legal protection (guardianship, curatorship) or not
Group 2:
Patients aged 2 years or above, with clinical signs of epilepsy associated to dysimmune encephalitis.
Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
Patients or relatives have been informed and given free informed and written consent to participate
Patients under legal protection (guardianship, curatorship) or not
Group 3:
Patients aged 18 years or above, without status epilepticus and/or dysimmune encephalitis.
Affiliation to a French social security system excluding "Aide Médicale" Etat (AME).
Patients or relatives have been informed and given free informed and written consent to participate
Patients under legal protection (guardianship, curatorship) or not

Exclusion Criteria13

Group 1:
Women with known or clinically detected pregnancy.
Patient deprived of liberty
Patients with known neurodegenerative disease.
Group 2:
Women with known or clinically detected pregnancy.
Patient deprived of liberty
Patients have been already treated by corticoids or IgIV.
Group 3:
Women with known or clinically detected pregnancy.
Patient deprived of liberty.
Patients with status epilepticus.
Patients with known neurodegenerative disease, brain tumor, severe head trauma, meningitis, subarachnoid hemorrhages, stroke.